ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Short Interest Update

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) saw a large decrease in short interest in the month of January. As of January 31st, there was short interest totalling 4,400 shares, a decrease of 15.4% from the January 15th total of 5,200 shares. Based on an average daily trading volume, of 11,900 shares, the short-interest ratio is presently 0.4 days.

ProShares Ultra Nasdaq Biotechnology Stock Down 0.3 %

NASDAQ BIB traded down $0.18 during trading hours on Monday, reaching $55.17. The company’s stock had a trading volume of 9,601 shares, compared to its average volume of 10,563. ProShares Ultra Nasdaq Biotechnology has a 1 year low of $47.19 and a 1 year high of $69.56. The firm’s 50-day moving average price is $53.40 and its 200-day moving average price is $59.49.

ProShares Ultra Nasdaq Biotechnology Increases Dividend

The business also recently declared a dividend, which was paid on Tuesday, December 31st. Shareholders of record on Monday, December 23rd were issued a $0.3964 dividend. This is an increase from ProShares Ultra Nasdaq Biotechnology’s previous dividend of $0.15. The ex-dividend date was Monday, December 23rd.

Institutional Investors Weigh In On ProShares Ultra Nasdaq Biotechnology

A number of hedge funds have recently made changes to their positions in the company. Jane Street Group LLC increased its stake in ProShares Ultra Nasdaq Biotechnology by 8.4% in the 3rd quarter. Jane Street Group LLC now owns 4,803 shares of the exchange traded fund’s stock worth $306,000 after acquiring an additional 374 shares during the last quarter. Crowley Wealth Management Inc. bought a new stake in ProShares Ultra Nasdaq Biotechnology in the fourth quarter worth $51,000. Finally, Tower Research Capital LLC TRC raised its stake in ProShares Ultra Nasdaq Biotechnology by 31.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,326 shares of the exchange traded fund’s stock valued at $270,000 after purchasing an additional 1,266 shares in the last quarter.

About ProShares Ultra Nasdaq Biotechnology

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.